The Presage^® ST2 Assay: analytical considerations and clinical applications for a high-sensitivity assay for measurement of soluble ST2

References

• Weinberg EO. ST2 protein in heart disease: from discovery to mechanisms and prognostic value. Biomark. Med. 3(5), 495–511 (2009).
   Google Scholar
• Miller AM, Liew FY. The IL-33/ST2 pathway – a new therapeutic target in cardiovascular disease. Pharmacol. Ther. 131(2), 179–186 (2011).
   PubMed Web of Science ®Google Scholar
• Dieplinger B, Januzzi JL Jr, Steinmair M et al. Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma – the Presage ST2 Assay. Clin. Chim. Acta 409(1–2), 33–40 (2009).
   PubMed Web of Science ®Google Scholar
• Tominaga S. A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS Lett. 258(2), 301–304 (1989).
   PubMed Web of Science ®Google Scholar
• Werenskiold AK, Hoffmann S, Klemenz R. Induction of a mitogen-responsive gene after expression of the Ha-ras oncogene in NIH 3T3 fibroblasts. Mol. Cell. Biol. 9(11), 5207–5214 (1989).
   PubMed Web of Science ®Google Scholar
• Schmitz J, Owyang A, Oldham E et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23(5), 479–490 (2005).
   PubMed Web of Science ®Google Scholar
• Kakkar R, Hei H, Dobner S, Lee RT. Interleukin 33 as a mechanically responsive cytokine secreted by living cells. J. Biol. Chem. 287(9), 6941–6948 (2012).
   PubMed Web of Science ®Google Scholar
• Mildner M, Storka A, Lichtenauer M et al. Primary sources and immunological prerequisites for sST2 secretion in humans. Cardiovasc. Res. 87(4), 769–777 (2010).
   PubMed Web of Science ®Google Scholar
• Weinberg EO, Shimpo M, De Keulenaer GW et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 106(23), 2961–2966 (2002).
   PubMed Web of Science ®Google Scholar
• Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J. Clin. Invest. 117(6), 1538–1549 (2007).
   PubMed Web of Science ®Google Scholar
• Seki K, Sanada S, Kudinova AY et al. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ. Heart Fail. 2(6), 684–691 (2009).
   PubMed Web of Science ®Google Scholar
• Kuroiwa K, Li H, Tago K et al. Construction of ELISA system to quantify human ST2 protein in sera of patients. Hybridoma 19(2), 151–159 (2000).
   Google Scholar
• Shimpo M, Morrow DA, Weinberg EO et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 109(18), 2186–2190 (2004).
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Morrow DA, Higgins LJ et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation 117(15), 1936–1944 (2008).
   PubMed Web of Science ®Google Scholar
• Eggers KM, Armstrong PW, Califf RM et al. ST2 and mortality in non-ST-segment elevation acute coronary syndrome. Am. Heart J. 159(5), 788–794 (2010).
   Google Scholar
• Dhillon OS, Narayan HK, Quinn PA, Squire IB, Davies JE, Ng LL. Interleukin 33 and ST2 in non-ST-elevation myocardial infarction: comparison with Global Registry of Acute Coronary Events Risk Scoring and NT-proBNP. Am. Heart J. 161(6), 1163–1170 (2011).
   PubMed Web of Science ®Google Scholar
• Kohli P, Bonaca MP, Kakkar R et al. Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. Clin. Chem. 58(1), 257–266 (2012).
   PubMed Web of Science ®Google Scholar
• Weir RA, Miller AM, Murphy GE et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J. Am. Coll. Cardiol. 55(3), 243–250 (2010).
   PubMed Web of Science ®Google Scholar
• Brown AM, Wu AH, Clopton P, Robey JL, Hollander JE. ST2 in emergency department chest pain patients with potential acute coronary syndromes. Ann. Emerg. Med. 50(2), 153–8, 158.e1 (2007).
   PubMed Web of Science ®Google Scholar
• Aldous SJ, Richards AM, Troughton R, Than M. ST2 has diagnostic and prognostic utility for all-cause mortality and heart failure in patients presenting to the emergency department with chest pain. J. Card. Fail. 18(4), 304–310 (2012).
   PubMed Web of Science ®Google Scholar
• Mueller T, Dieplinger B, Gegenhuber A, Poelz W, Pacher R, Haltmayer M. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin. Chem. 54(4), 752–756 (2008).
   PubMed Web of Science ®Google Scholar
• Rehman SU, Mueller T, Januzzi JL Jr. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J. Am. Coll. Cardiol. 52(18), 1458–1465 (2008).
   PubMed Web of Science ®Google Scholar
• Manzano-Fernández S, Mueller T, Pascual-Figal D, Truong QA, Januzzi JL. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am. J. Cardiol. 107(2), 259–267 (2011).
   PubMed Web of Science ®Google Scholar
• Pascual-Figal DA, Manzano-Fernández S, Boronat M et al. Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur. J. Heart Fail. 13(7), 718–725 (2011).
   PubMed Web of Science ®Google Scholar
• Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, Lee RT. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 107(5), 721–726 (2003).
   PubMed Web of Science ®Google Scholar
• Pascual-Figal DA, Ordoñez-Llanos J, Tornel PL et al.; MUSIC Investigators. Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. J. Am. Coll. Cardiol. 54(23), 2174–2179 (2009).
   PubMed Web of Science ®Google Scholar
• Daniels LB, Clopton P, Iqbal N, Tran K, Maisel AS. Association of ST2 levels with cardiac structure and function and mortality in outpatients. Am. Heart J. 160(4), 721–728 (2010).
   PubMed Web of Science ®Google Scholar
• Ky B, French B, McCloskey K et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ. Heart Fail. 4(2), 180–187 (2011).
   PubMed Web of Science ®Google Scholar
• Ky B, French B, Levy WC et al. Multiple biomarkers for risk prediction in chronic heart failure. Circ. Heart Fail. 5(2), 183–190 (2012).
   PubMed Web of Science ®Google Scholar
• Bayes-Genis A, de Antonio M, Galán A et al. Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure. Eur. J. Heart Fail. 14(1), 32–38 (2012).
   PubMed Web of Science ®Google Scholar
• Broch K, Ueland T, Nymo SH et al. Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology. Eur. J. Heart Fail. 14(3), 268–277 (2012).
   PubMed Web of Science ®Google Scholar
• Boisot S, Beede J, Isakson S et al. Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. J. Card. Fail. 14(9), 732–738 (2008).
   PubMed Web of Science ®Google Scholar
• Bayes-Genis A, Pascual-Figal D, Januzzi JL et al. Soluble ST2 monitoring provides additional risk stratification for outpatients with decompensated heart failure. Rev. Esp. Cardiol. 63(10), 1171–1178 (2010).
   PubMed Web of Science ®Google Scholar
• Januzzi JL Jr, Peacock WF, Maisel AS et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J. Am Coll. Cardiol. 50(7), 607–613 (2007).
   PubMed Web of Science ®Google Scholar
• Dieplinger B, Gegenhuber A, Haltmayer M, Mueller T. Evaluation of novel biomarkers for the diagnosis of acute destabilised heart failure in patients with shortness of breath. Heart 95(18), 1508–1513 (2009).
   PubMed Web of Science ®Google Scholar
• Martinez-Rumayor A, Camargo CA, Green SM, Baggish AL, O’Donoghue M, Januzzi JL. Soluble ST2 plasma concentrations predict 1-year mortality in acutely dyspneic emergency department patients with pulmonary disease. Am. J. Clin. Pathol. 130(4), 578–584 (2008).
   PubMed Web of Science ®Google Scholar
• Rehman SU, Martinez-Rumayor A, Mueller T, Januzzi JL Jr. Independent and incremental prognostic value of multimarker testing in acute dyspnea: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Clin. Chim. Acta 392(1–2), 41–45 (2008).
   PubMed Web of Science ®Google Scholar
• Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RR, Januzzi JL. Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea. Circ. Heart Fail. 2(4), 311–319 (2009).
   PubMed Web of Science ®Google Scholar
• Dieplinger B, Gegenhuber A, Kaar G, Poelz W, Haltmayer M, Mueller T. Prognostic value of established and novel biomarkers in patients with shortness of breath attending an emergency department. Clin. Biochem. 43(9), 714–719 (2010).
   Web of Science ®Google Scholar
• Januzzi JL Jr, Rehman S, Mueller T, van Kimmenade RR, Lloyd-Jones DM. Importance of biomarkers for long-term mortality prediction in acutely dyspneic patients. Clin. Chem. 56(12), 1814–1821 (2010).
   Google Scholar
• Socrates T, deFilippi C, Reichlin T et al. Interleukin family member ST2 and mortality in acute dyspnoea. J. Intern. Med. 268(5), 493–500 (2010).
   PubMed Web of Science ®Google Scholar
• Shah KB, Kop WJ, Christenson RH et al. Prognostic utility of ST2 in patients with acute dyspnea and preserved left ventricular ejection fraction. Clin. Chem. 57(6), 874–882 (2011).
   PubMed Web of Science ®Google Scholar
• Dieplinger B, Egger M, Poelz W, Haltmayer M, Mueller T. Long-term stability of soluble ST2 in frozen plasma samples. Clin. Biochem. 43(13–14), 1169–1170 (2010).
   Google Scholar
• Lu J, Snider JV, Grenache DG. Establishment of reference intervals for soluble ST2 from a United States population. Clin. Chim. Acta 411(21–22), 1825–1826 (2010).
   PubMed Web of Science ®Google Scholar
• Dieplinger B, Egger M, Poelz W, Gabriel C, Haltmayer M, Mueller T. Soluble ST2 is not independently associated with androgen and estrogen status in healthy males and females. Clin. Chem. Lab. Med. 49(9), 1515–1518 (2011).
   Google Scholar
• Mueller T, Zimmermann M, Dieplinger B, Ankersmit HJ, Haltmayer M. Comparison of plasma concentrations of soluble ST2 measured by three different commercially available assays: The MBL ST2 assay, the Presage ST2 Assay, and the R&D ST2 assay. Clin. Chim. Acta 413(19–20), 1493–1494 (2012).
   Google Scholar
• Fousteris E, Melidonis A, Panoutsopoulos G et al. Toll/interleukin-1 receptor member ST2 exhibits higher soluble levels in Type 2 diabetes, especially when accompanied with left ventricular diastolic dysfunction. Cardiovasc. Diabetol. 10, 101 (2011).
   PubMedGoogle Scholar
• Pascual-Figal DA, Garrido IP, Blanco R et al. Soluble ST2 is a marker for acute cardiac allograft rejection. Ann. Thorac. Surg. 92(6), 2118–2124 (2011).
   Google Scholar
• Sato YZ, Molkara DP, Daniels LB et al. Cardiovascular biomarkers in acute Kawasaki disease. Int. J. Cardiol. doi:10.1016/j.ijcard.2011.06.065 (2011) (Epub ahead of print).
   Google Scholar
• Granne I, Southcombe JH, Snider JV et al. ST2 and IL-33 in pregnancy and pre-eclampsia. PLoS One 6(9), e24463 (2011).
   PubMed Web of Science ®Google Scholar
• Dieplinger B, Egger M, Koehler W et al. Prognostic value of soluble ST2 in an unselected cohort of patients admitted to an intensive care unit – the Linz Intensive Care Unit (LICU) study. Clin. Chim. Acta 413(5–6), 587–593 (2012).
   PubMed Web of Science ®Google Scholar
• Sawaya H, Sebag IA, Plana JC et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes and trastuzumab. Circ. Cardiovasc. Imaging 5(5), 596–603 (2012).
   Google Scholar
• Apple FS, Steffen LM, Pearce LA, Murakami MM, Luepker RV. Increased cardiac troponin I as measured by a high-sensitivity assay is associated with high odds of cardiovascular death: the Minnesota Heart Survey. Clin. Chem. 58(5), 930–935 (2012).
   Google Scholar
• Alves-Filho JC, Sônego F, Souto FO et al. Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection. Nat. Med. 16(6), 708–712 (2010).
   PubMed Web of Science ®Google Scholar
• Brunner M, Krenn C, Roth G et al. Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma. Intensive Care Med. 30(7), 1468–1473 (2004).
   PubMed Web of Science ®Google Scholar
• Hoogerwerf JJ, Tanck MW, van Zoelen MA, Wittebole X, Laterre PF, van der Poll T. Soluble ST2 plasma concentrations predict mortality in severe sepsis. Intensive Care Med. 36(4), 630–637 (2010).
   PubMed Web of Science ®Google Scholar
• Wagenaar JF, Gasem MH, Goris MG et al. Soluble ST2 levels are associated with bleeding in patients with severe Leptospirosis. PLoS Negl. Trop. Dis. 3(6), e453 (2009).
   PubMed Web of Science ®Google Scholar
• Becerra A, Warke RV, de Bosch N, Rothman AL, Bosch I. Elevated levels of soluble ST2 protein in dengue virus infected patients. Cytokine 41(2), 114–120 (2008).
   PubMed Web of Science ®Google Scholar
• Oshikawa K, Kuroiwa K, Tago K et al. Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am. J. Respir. Crit. Care Med. 164(2), 277–281 (2001).
   PubMed Web of Science ®Google Scholar
• Ali M, Zhang G, Thomas WR et al. Investigations into the role of ST2 in acute asthma in children. Tissue Antigens 73(3), 206–212 (2009).
   PubMedGoogle Scholar
• Tajima S, Oshikawa K, Tominaga S, Sugiyama Y. The increase in serum soluble ST2 protein upon acute exacerbation of idiopathic pulmonary fibrosis. Chest 124(4), 1206–1214 (2003).
   PubMed Web of Science ®Google Scholar
• Hacker S, Lambers C, Pollreisz A et al. Increased soluble serum markers caspase-cleaved cytokeratin-18, histones, and ST2 indicate apoptotic turnover and chronic immune response in COPD. J. Clin. Lab. Anal. 23(6), 372–379 (2009).
   PubMed Web of Science ®Google Scholar
• Oshikawa K, Kuroiwa K, Tokunaga T et al. Acute eosinophilic pneumonia with increased soluble ST2 in serum and bronchoalveolar lavage fluid. Respir. Med. 95(6), 532–533 (2001).
   PubMed Web of Science ®Google Scholar
• Scott PA, Townsend PA, Ng LL et al. Defining potential to benefit from implantable cardioverter defibrillator therapy: the role of biomarkers. Europace 13(10), 1419–1427 (2011).
   Google Scholar
• Zhang HF, Xie SL, Cheng YX et al. Altered serum levels of IL-33 in patients with advanced systolic chronic heart failure: correlation with oxidative stress. J. Transl. Med. 10(1), 120 (2012).
   Google Scholar
• Porcel JM, Martínez-Alonso M, Cao G, Bielsa S, Sopena A, Esquerda A. Biomarkers of heart failure in pleural fluid. Chest 136(3), 671–677 (2009).
   Google Scholar
• Bartunek J, Delrue L, Van Durme F et al. Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. J. Am. Coll. Cardiol. 52(25), 2166–2174 (2008).
   PubMed Web of Science ®Google Scholar
• Szerafin T, Brunner M, Horváth A et al. Soluble ST2 protein in cardiac surgery: a possible negative feedback loop to prevent uncontrolled inflammatory reactions. Clin. Lab. 51(11–12), 657–663 (2005).
   Google Scholar
• Szerafin T, Niederpold T, Mangold A et al. Secretion of soluble ST2 - possible explanation for systemic immunosuppression after heart surgery. Thorac. Cardiovasc. Surg. 57(1), 25–29 (2009).
   Google Scholar
• Bruneau S, Le Berre L, Hervé C et al. Potential role of soluble ST2 protein in idiopathic nephrotic syndrome recurrence following kidney transplantation. Am. J. Kidney Dis. 54(3), 522–532 (2009).
   Google Scholar
• Bao YS, Na SP, Zhang P et al. Characterization of interleukin-33 and soluble ST2 in serum and their association with disease severity in patients with chronic kidney disease. J. Clin. Immunol. 32(3), 587–594 (2012).
   PubMed Web of Science ®Google Scholar
• Roth GA, Zimmermann M, Lubsczyk BA et al. Up-regulation of interleukin 33 and soluble ST2 serum levels in liver failure. J. Surg. Res. 163(2), e79–e83 (2010).
   Google Scholar
• Wang J, Cai Y, Ji H et al. Serum IL-33 levels are associated with liver damage in patients with chronic hepatitis B. J. Interferon Cytokine Res. 32(6), 248–253 (2012).
   Google Scholar
• Ouziel R, Gustot T, Moreno C et al. The ST2 pathway is involved in acute pancreatitis: a translational study in humans and mice. Am. J. Pathol. 180(6), 2330–2339 (2012).
   Google Scholar
• Pastorelli L, Garg RR, Hoang SB et al. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc. Natl Acad. Sci. USA 107(17), 8017–8022 (2010).
   PubMed Web of Science ®Google Scholar
• Díaz-Jiménez D, Núñez LE, Beltrán CJ et al. Soluble ST2: a new and promising activity marker in ulcerative colitis. World J. Gastroenterol. 17(17), 2181–2190 (2011).
   PubMed Web of Science ®Google Scholar
• Beltrán CJ, Núñez LE, Díaz-Jiménez D et al. Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 16(7), 1097–1107 (2010).
   PubMed Web of Science ®Google Scholar
• Shimizu M, Matsuda A, Yanagisawa K et al. Functional SNPs in the distal promoter of the ST2 gene are associated with atopic dermatitis. Hum. Mol. Genet. 14(19), 2919–2927 (2005).
   PubMed Web of Science ®Google Scholar
• Wakatabi K, Komine M, Meephansan J et al. The levels of soluble ST2 in sera and bullous fluid from patients with bullous pemphigoid. Eur. J. Dermatol. 22(3), 333–336 (2012).
   Google Scholar
• Talabot-Ayer D, McKee T, Gindre P et al. Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Joint Bone Spine 79(1), 32–37 (2012).
   PubMed Web of Science ®Google Scholar
• Hong YS, Moon SJ, Joo YB et al. Measurement of interleukin-33 (IL-33) and IL-33 receptors (sST2 and ST2L) in patients with rheumatoid arthritis. J. Korean Med. Sci. 26(9), 1132–1139 (2011).
   PubMed Web of Science ®Google Scholar
• Mok MY, Huang FP, Ip WK et al. Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus. Rheumatology (Oxford) 49(3), 520–527 (2010).
   PubMed Web of Science ®Google Scholar
• Kuroiwa K, Arai T, Okazaki H, Minota S, Tominaga S. Identification of human ST2 protein in the sera of patients with autoimmune diseases. Biochem. Biophys. Res. Commun. 284(5), 1104–1108 (2001).
   PubMed Web of Science ®Google Scholar
• Sahlander K, Larsson K, Palmberg L. Increased serum levels of soluble ST2 in birch pollen atopics and individuals working in laboratory animal facilities. J. Occup. Environ. Med. 52(2), 214–218 (2010).
   Google Scholar
• Oshikawa K, Yanagisawa K, Ohno S, Tominaga S, Sugiyama Y. Expression of ST2 in helper T lymphocytes of malignant pleural effusions. Am. J. Respir. Crit. Care Med. 165(7), 1005–1009 (2002).
   PubMed Web of Science ®Google Scholar
• Gillibert-Duplantier J, Duthey B, Sisirak V et al. Gene expression profiling identifies sST2 as an effector of ErbB2-driven breast carcinoma cell motility, associated with metastasis. Oncogene 31(30), 3516–3524 (2012).
   PubMed Web of Science ®Google Scholar
• Rechardt M, Shiri R, Matikainen S, Viikari-Juntura E, Karppinen J, Alenius H. Soluble IL-1RII and IL-18 are associated with incipient upper extremity soft tissue disorders. Cytokine 54(2), 149–153 (2011).
   Google Scholar
• Kanda M, Ohto-Ozaki H, Kuroiwa K, Tominaga S, Watanabe E, Iwahana H. Elevation of ST2 protein levels in cerebrospinal fluid following subarachnoid hemorrhage. Acta Neurol. Scand. 113(5), 327–333 (2006).
   Google Scholar
• Lin CY, Pfluger CM, Henderson RD, McCombe PA. Reduced levels of interleukin 33 and increased levels of soluble ST2 in subjects with amyotrophic lateral sclerosis. J. Neuroimmunol. 249(1–2), 93–95 (2012).
   PubMed Web of Science ®Google Scholar